Redefinição do espectro clínico do Síndrome de Rett e Síndrome "Rett-like" by Sofia Ferreira de Lemos Bastos Cardoso
  
 
 
 
 
 
 
 
 
Redefinição do espectro clínico do Síndrome de Rett e 
Síndromes “Rett-like” 
REDEFINITION OF THE PHENOTYPES OF RETT AND “RETT-LIKE” 
SYNDROMES 
 
 
 
 
 
SOFIA FERREIRA DE LEMOS BASTOS CARDOSO 
 
 
 
 
Dissertação em Mestrado Integrado em Medicina 
 
 
 
 
 
Porto, 2013
   2 
 
 
 
SOFIA FERREIRA DE LEMOS BASTOS CARDOSO 
 
 
 
 
REDEFINIÇÃO DO ESPECTRO CLINICO DO SÍNDROME DE RETT E 
SÍNDROMES “RETT-LIKE” 
REDEFINITION OF THE PHENOTYPES OF RETT AND “RETT-LIKE” 
SYNDROMES 
 
 
 
 
Dissertação de Candidatura ao grau de Mestre em Medicina submetida ao Instituto de 
Ciências Biomédicas de Abel Salazar da Universidade do Porto.  
 
Orientador – Prof. Doutora Teresa Temudo 
Grau académico: Doutorada  
Título profissional: Neuropediatra do CHP e Professora auxiliar convidada de Pediatria 
do ICBAS-CHP 
Afiliação – Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto 
Co-orientador: Dr.ª Mafalda Barbosa 
Grau académico: Doutoranda (Icahn School of Medicine at Mount Sinai, Nova Iorque, 
E.U.A.) 
Título profissional: Médica especialista em Genética Médica 
Afiliação - Icahn School of Medicine at Mount Sinai, Nova Iorque, E.U.A. e Centro de 
Genética Médica Jacinto Magalhães, Centro Hospitalar do Porto, Porto, Portugal  
   3 
LISTA DE ABREVIATURAS 
 
 
CDKL5 - Cyclin-dependent kinase-like 5 
EEG – Electroencephalography 
FOXG1 - Gene forkhead box G1 
GI - gastrointestinal 
MECP2 - Methyl CpG binding protein 2  
MRI - Magnetic resonance imaging 
RTT – Rett Syndrome 
 
  
   4 
Resumo 
 
O Síndrome de Rett é uma doença do neurodesenvolvimento que afeta 
aproximadamente 1 em cada 10,000 indivíduos do sexo feminino. A mutação no gene methyl-
CpG-binding protein 2, ligado ao X, é causadora do síndrome na maioria dos doentes. Para 
além desta mutação, mutações noutros genes têm vindo a ser associadas a formas atípicas: no 
gene forkhead box G1, envolvido na variante congénita do síndrome de Rett e no gene cyclin-
dependent kinase-like 5 envolvido no Sindrome de Rett com encefalopatia epilética de início 
precoce. 
Os critérios de diagnóstico do Síndrome de Rett foram pela última vez atualizados em 
2010 por Neul et al. Após a revisão de um vasto número de relatos de caso e séries de casos 
publicados onde são descritos doentes com mutações em genes associadas às variantes de 
RTT, tentamos delinear uma relação genótipo-fenótipo para doentes com mutações nos genes 
forkhead box G1 e cyclin-dependent kinase-like. Este conhecimento tem aplicação na prática 
clinica dado que permite um refinado reconhecimento clínico da doença e dirigir o estudo 
genético de forma mais precisa para cada uma das variantes do Síndrome de Rett.  
Por outro lado, com a definição de um fenótipo mais comum para cada uma das 
mutações, foi possível uma comparação com os critérios de classificação atuais para variantes 
de Síndrome de Rett. Concluímos, que poucos casos descritos como variantes cumprem os 
atuais critérios de diagnóstico para variante de Rett, e uma vez que se definem com 
características específicas e individualizantes podem possivelmente emergir como uma 
entidade independente. 
 
 
 
 
 
Palavras-Chave: Síndrome de Rett, Variante atípica do Síndrome de Rett, gene FOXG1, gene 
CDKL5, relação genótipo- fenótipo 
  
   5 
Abstract 
 
Rett syndrome is a severe neurodevelopmental disease that affects approximately 1 in 
10,000 live females and is caused, in the majority of the typical cases, by mutations in the X-
linked methyl-CpG-binding protein gene. Mutations on other genes have also been associated 
with atypical variants of the Rett syndrome: in the forkhead box G1 gene - involved in the 
congenital variant – and in the cyclin-dependent kinase-like 5 gene - involved in the early-
onset epileptic encephalopathy variant of the syndrome.  
The diagnostic criteria of Rett Syndrome have been updated in 2010 by Neul et al. 
providing a key to diagnose of the Rett variants. Given the vast number of case reports of 
patients with mutations in the genes associated with the Rett Syndrome variants, we were 
able to refine the genotype-phenotype correlation for the forkhead box G1 gene and for 
cyclin-dependent kinase-like 5 gene. This knowledge has clinical application, given that it 
allows for a more refined recognition of the clinical picture and to more accurately target the 
genetic testing. 
Through the analysis of a vast number of reported cases of each mutation we were 
able to build an approximate phenotype for each mutation, which in turn is essential for easier 
and faster recognition of the disease among physicians (and a valuable key in the decision of 
the performance of the genetic screening). On the other hand, taking into account a more 
broad phenotype, we compared the variants of Rett Syndrome with the current diagnostic 
criteria and verified that only few patients do fulfill the diagnostic criteria of a Rett variant. We 
concluded that mutations in these two genes and the respective associated phenotypes 
present specific characteristics, and may be considered as new independent entities. 
 
 
 
 
 
 
Key Words: Rett Syndrome, Atypical Rett Syndrome, FOXG1 gene, CDKL5 gene, genotype-
phenotype correlation 
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Introduction 
 
 History of the disease - RTT and current diagnostic criteria 
 
Rett syndrome (RTT) is a severe neurodevelopmental disease that affects 
approximately 1 in 10,000 live female births(1). This syndrome, originally described in the 
1960’s by Andreas Rett, is characterized by loss of spoken language and hand use with the 
development of distinctive hand stereotypies(2). The eponym Rett’s Syndrome first appeared 
in 1983 when Hagberg wrote his first paper about the specific clinical features of this 
syndrome(3). 
The gestation and birth are usually uneventful and head circumference at birth is 
normal(4). The first psychomotor anomaly appears during the first year of life, as a nonspecific 
slowdown in development. Patients rarely crawl and unsupported walk is usually delayed or 
never reached.  
By the first or second year, loss of acquired fine motor, intellectual and communication 
abilities occurs: children lose interest in the environment and ability to speak, manipulate 
objects and play. Concomitantly they initiate repetitive movements with their hands and other 
body parts – stereotypies. The following stage, which can last from three to five years,  is 
characterized by rapid regression. During this stage behavioral disturbances (unexpected 
screaming attacks, laughing spells and nocturnal insomnia) are common. Throughout the 
months of regression, stereotypies become more frequent and usually one pattern 
predominates (washing, clapping, wringing or tapping the hands). Autistic features may be 
evident (4). 
Following this period of regression, there is frequently a phase of improvement of 
social skills, sometimes accompanied by a partial regain of lost abilities, such as the use of 
words. These girls remain profoundly intellectually disabled and present with a particularly 
good eye contact (4). 
By this time, the combination of a previous personal history of developmental 
regression, deceleration of head growth, severe intellectual disability, continuous hand 
stereotypies, inability to use the hands and a striking good eye gaze suggest the diagnosis of 
RTT(5).  The presence of other alterations such as bruxism, breathing dysfunction, peripheral 
vasomotor disturbances (hypotrophic small and cold feet)(6) and scoliosis favore the diagnosis. 
Epilepsy is also present in the majority of these children (up to 80%)(7). Seizures usually start 
during the third stage of the disease (around 5 years old) and become less frequent with aging 
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(8). As neuromotor functions slowly decline some parkinsonian signs such as, ataxia, limb 
wasting, dystonia, pyramidal signs, bradikinesia and rigidity may appear. (9). 
The last stage is initiated when walkers lose the capacity of walking, or when patients 
who never acquired independent gait, are more than 10 years old. At this stage, hand 
stereotypies become less frequent faithful to its pattern (4). 
RTT is quite underdiagnosed in adulthood, probably due to the much less exuberant 
stereotypies. By this time, patients are often wheelchair dependent. One third of the cases die, 
inexplicably, during the first two decades of life(4). 
Some patients present with a core of symptoms of classical RTT, but show considerable 
variation in type and age of onset, severity of impairment and profile of clinical course. 
Consequently, RTT variants have been described (6, 10): 
o Preserved speech variant (PSV): characterized by the recovery of  speech to some 
extent;  
o Congenital variant: without a normal period of development before regression;  
o Early seizure variant: in which onset of seizures occurs before the regression; 
o Forme fruste: with milder/incomplete clinical course (regression between 1 and 3 
years). 
 
Diagnostic criteria for RTT are periodically reviewed in order to clarify and simplify the 
diagnosis of this syndrome. Neul et al. (2010) (11) published the last Revised RTT Diagnostic 
Criteria for typical or classic RTT and for atypical RTT. According to these new criteria, history 
of regression followed by a period of recovery/stabilization is obligatory to establish the 
diagnosis of both typical and atypical RTT. 
Revised Clinical Criteria for Typical RTT: Necessary criteria are now limited to the presence 
of regression plus four main criteria. The deceleration of head growth was eliminated from the 
necessary criteria because this feature is not found in all cases. However, it is still an important 
clinical sign that should raise the suspicion for the diagnosis. The supportive criteria have been 
entirely eliminated from the diagnostic criteria for typical RTT (Tab.1). 
Revised Clinical Criteria for Atypical RTT: In addition to having regression, individuals must 
have at least two of the four main criteria and five of eleven supportive criteria (Table1).  
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Table 1: Revised Diagnostic Criteria for Rett Syndrome (RTT)  in Neul et al (2010) 
 
RTT diagnostic criteria 2010 
Consider diagnosis when postnatal deceleration of head growth observed 
Required for 
typical or classic 
RTT 
1. A period of regression followed by recovery or stabilization 
2. All main criteria and all exclusion criteria 
3. Supportive criteria are not required, although often present in typical RTT 
Required for 
atypical or 
variant RTT 
1. A period of regression followed by recovery or stabilization 
2. At least 2 of the 4 main criteria 
3. 5 out of 11 supportive criteria 
Main criteria 
1. Partial or complete loss of acquired purposeful hand skills 
2. Partial or complete loss of acquired spoken language 
3. Gait abnormalities: Impaired (dyspraxic) or absence of ability 
4. Stereotypic hand movements such as hand wringing/squeezing, 
clapping/tapping, mouthing and washing/rubbing automatisms 
Exclusion criteria 
for typical RTT 
1. Brain injury secondary to trauma (peri- or postnatally), neurometabolic disease, 
or severe infection that causes neurological problems 
2. Grossly abnormal psychomotor development in first 6 months of life 
Supportive 
criteria for 
atypical RTT 
1. Breathing disturbances when awake 
2. Bruxism when awake 
3. Impaired sleep pattern 
4. Abnormal muscle tone 
5. Peripheral vasomotor disturbances 
6. Scoliosis/kyphosis 
7. Growth retardation 
8. Small cold hands and feet 
9. Inappropriate laughing/screaming spells 
10. Diminished response to pain 
11. Intense eye communication - «eye pointing» 
 
The frequencies  at which the new supportive criteria are observed in atypical RTT 
were reported by Percy, et al. (2010)(11) : periodic breathing (61%), bruxism (83%), sleep 
disruption (72%), abnormal gait (93%), cold feet (19%), scoliosis (36%), aerophagia (38%), 
lower limb muscle atrophy (21%), laughing/screaming spells (63%), reduced nociception (71%) 
and intense eye contact (66%). 
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In 1999, Amir and colleagues discovered that mutations in the gene encoding Methyl-
CpGbinding protein 2 (MECP2) are associated both with rare familial cases of RTT as well as 
with the more common sporadic occurrences of RTT (12). This gene is located in the long arm 
of the X chromosome, at band q28 and is subject to X-chromosome inactivation(13). The fact 
that mutations in this gene have been mainly identified in female patients, and the virtual 
absence of affected males, suggests an X-linked dominant inheritance pattern (3). As a matter 
of fact, females are heterozygous for mutations in MECP2 gene and the few males reported 
have an XXY karyotype or MECP2 mutations in a mosaic state. 
In male patients the phenotype is wide and can range from a severe epileptic 
encephalopathy seen in patients who do have the MECP2 mutations, to patients with a 
phenotype that resembles female patients with RTT (usually with mosaic form mutations or 
the Klinefelter syndrome) or even patients with a clinical picture that does not resemble RTT 
and have MECP2 mutations infrequently found in female RTT patients(14, 15). 
MECP2 mutations are present in classic RTT cases in 75% to 95% (11, 16-19) and only in 
20-44% of the patients with RTT variants  (17, 19, 20). However, Percy et al. (2010) (11) 
reported a higher incidence of mutations in RTT variants of 73%. It’s worth mentioning that the 
mutations found in patients with RTT variant can be identical to those found in classic RTT. 
MECP2 mutations have also been identified in about 50% of PSV cases and in lower percentage 
on the other variants (17). 
Although it is a genetic disorder, 99.5% of RTT cases are sporadic(21).  The de novo 
mutation often occurs on the paternal X chromosome, however, rare cases of germline 
mosaicism of MECP2(22) and of mildly affected or asymptomatic mothers (due to favorably 
skewed X-chromosome inactivation) passing on MECP2 mutations occur, accounting for rare 
familial cases(14). 
Rare individuals with mutations in MECP2 present with other neurodevelopmental 
conditions such as autism(23), Angelman syndrome-like presentation(24), and non-specific 
intellectual disability; still they lack important defining features of the syndrome and the 
diagnosis cannot be made. These clinical phenotypes emphasize that mutations in MECP2 are 
not synonymous of RTT and that a mutation in MECP2 is not sufficient to make the diagnosis of 
RTT. Because MECP2 mutations are neither necessary nor sufficient to make the diagnosis of 
RTT, RTT remains a clinical diagnosis(11). 
There are significant clinical differences between RTT patients with and without 
MECP2 mutation. Among those without the mutation, only few had a normal development 
during the first year of life and a regressive period was not evident; besides this, autistic 
behavior, when present, is noticed earlier. This suggests that these children may never have 
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been normal. Additionally, patients with no detected MECP2 gene mutation have worse social 
contact and less stereotypies. Eye pointing and an ataxic-rigid gait seem to be important clues 
to the presence of mutation on the MECP2 gene (19); these features may be of use in the 
decision of the necessity of a MECP2 mutation screening. 
 The existence of RTT patients without MECP2 mutations suggests that additional 
genetic factors might determine this disorder.  
 
The congenital variant is one of the variants of atypical RTT, and, as said before, 
although up to 95% of classical RTT and 40% of atypical RTT are caused by mutations in the 
MECP2 gene, only few girls described as congenital variants have mutations in MECP2 (25, 26). 
Initially described by Rolando, the affected girls have an overlapping phenotype with classic 
RTT but in addition they were hypotonic and developmentally delayed from the very first 
months of life (27). In 2005, Shoichet et al. reported a 7-year-old girl exhibiting severe 
cognitive disability associated with a significant asymmetrical enlargement of the lateral 
ventricles, frontal and parietal myelination defects, complete agenesis of the corpus callosum, 
seizures, tetraplegia and microcephaly with a balanced de novo translocation t(2; 14)(p22;q12) 
with a neighboring inversion in chromosome 14q12 that disrupts the wingedhelix transcription 
factor forkhead box G1 (FOXG1) gene(28). Later, three 14q12 interstitial deletions 
encompassing FOXG1 were detected in 2 girls with psychomotor retardation, epilepsy, 
microcephaly, and unusual facial features, and in a 10-month old male patient with intellectual 
disability, microcephaly, and facial dysmorphism (29-31). Finally, the importance of the FOXG1 
gene was reinforced by linking FOXG1 –null mutations and the congenital variant of Rett 
syndrome (RTT) in 2 unrelated girls(32). 
The most consistent RTT-like features observed in these patients were microcephaly, 
either of congenital onset or secondary to early postnatal deceleration of head growth, hand 
stereotypies, scoliosis, and some autonomic features including hypotrophic feet, bloating, and 
impaired nociperception. However, because RTT is a neurodevelopmental disorder affecting 
almost exclusively females, large molecular screening of the FOXG1 gene were initially carried 
out in cohorts of female individuals suffering from typical and atypical forms of RTT(33-35), 
and this may explain why only few male patients have been reported to date with FOXG1 point 
mutations (36). 
 
The early seizure RTT variant was initially described by Hanefeld in 1985, who reported 
a girl with infantile spasms and hypsarrhythmia in early life (26, 37). This Hanefeld variant 
presents a phenotypic overlap with West syndrome and is also known as infantile spasm 
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syndrome, X-linked (ISSX). ISSX is characterized by the triad of infantile spasms, 
hypsarrhythmia, and severe to profound intellectual disability. In 2003, Kalscheuer et al. 
described 2 unrelated female patients with apparently balanced translocations: 
46,X,t(X;7)(p22.3;p15) in 1 case and 46,X,t(X;6)(p22.3;q14) in the other(38). The 2 patients had 
a similar phenotype: severe early-onset infantile spasms with hypsarrythmia and profound 
global developmental arrest. In both patients, the X-chromosomal breakpoints disrupted 
CDKL5. In view of the phenotypic overlap between the Hanefeld variant and ISSX, 2 
independent groups (in 2004) looked for CDKL5 mutations in patients who had been diagnosed 
with RTT or a variant of RTT and in whom no MECP2 mutation had been identified. They 
identified point mutations in the CDKL5 gene in a subset of patients with a clinical picture 
resembling the early-onset RTT variant or with a history of early-onset seizures (39, 40). 
Noteworthy,  the seizures observed in the affected individuals reported in these studies and 
those mentioned in other published reports of CDKL5 defects (41) were generally difficult to 
control with anticonvulsant therapies. The CDKL5 gene was subsequently analyzed in patients 
with both classic and atypical variants of RTT by several groups, but mutations were identified 
only in patients with seizure onset before 6 months of age (20, 42, 43). 
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Objectives 
 
The purpose of this study is to gather a valuable number of articles with phenotypical 
descriptions of patients with either a mutation on CDKL5 or FOXG1. We aim define a specific 
phenotype for each gene, that would allow physicians to use the clinical information to 
request targeted genetic testing 
Methods 
 
In order to review the highest number of case reports on RTT and its variants a 
systematic search was performed on MEDLINE. The selected MESH terms were: human FOXG1 
protein, human, human CDKL5 protein, Rett Syndrome, Zappella Variant, Atypical Rett 
Syndrome, Rett Syndrome, Preserved Speech Variant. In addition, the reference lists of the 
selected papers were examined for additional studies.  The search was not restricted by date 
and included articles until January 2013. We selected for studies providing clinical description 
of patients with mutations on CDKL5 or FOXG1. We extracted all the clinical data in order to 
identify the required criteria for atypical or variant RTT.  
 For statistical analysis we used IBM® SPSS® Statistics Version 20.0 and descriptive 
analysis was conducted. 
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Results 
 
We identified 53 citations in the initial search strategy, 6 were excluded for not being 
related with the issue, and 4 for providing only literature review. From the 43 articles 
considered to be relevant and selected for this review, 25 pertain to patients with CDKL5 
mutations, and 18 with FOXG1. The selected studies included 161 patients, 121 had mutations 
in CDKL5 and 40 in the FOXG1 gene. 
Overall, 89,9% of the patients were females and 10,1% males (Table 2). Analyzing the 
CDKL5 group, 93,4% of the patients were females and 6,6% males; the median age on the last 
evaluation was 5 years (minimum: 0,5; maximum: 41 years).  On the other hand, on the FOXG1 
group, 78,9% were females and 21,1% males; the median age on the last evaluation was 4 
years (minimum: 0,8; maximum: 41 years).  
 A period of regression followed by recovery or stabilization was found in 16,5% of the 
individuals with mutations in CDKL5, and in 22,5% of the patients with mutations in FOXG1.
 Partial or complete loss of acquired purposeful hand skills was identified in 4,1 % of 
the individuals with mutations in CDKL5, and in 2,5% of the patients with mutations in FOXG1 
(Table 2). However the vast majority of the remaining patients did not even acquire purposeful 
hand skills. 
 Only 5% of the individuals in the CDLK5 group showed partial or complete loss of 
acquired spoken language, while the rest never acquired language. None of the patients with 
FOXG1 mutation ever acquired language. 
 Gait abnormalities, either impaired (dyspraxic) or absence of ability, were evident in 
86,8% of the individuals in the CDKL5 group, and in 90% of the patients in the FOXG1 group. 
 Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, 
mouthing and washing/rubbing automatisms were described in 78,5% of the individuals with 
mutations in CDKL5, and in 87,5% of the patients with mutations in FOXG1. 
 In summary, 73,6% of the patients with CDKL5 mutation and 77,5% of the patients 
with FOXG1 mutation meet the two out of four  main criteria necessary to establish the 
diagnosis of atypical RTT. 
 Considering the supportive criteria for diagnosis of the atypical RTT in the patients 
with mutations in CDKL5: 77,7% abnormal muscle tone, 25,6% peripheral vasomotor 
disturbances,  20,7% impaired sleep pattern, 19% presented breathing disturbances, 16,5% 
growth retardation, 14% scoliosis or kyphosis, 13,2% intense eye communication - «eye 
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pointing», 12,4% bruxism, 11,6% small cold hands and feet and 9,1% inappropriate laughing or 
screaming spells. 
Considering the supportive criteria for diagnosis of the atypical RTT in the patients 
with mutations in FOXG1: 80%  presented abnormal muscle tone, 37,5% small cold hands and 
feet, 35% peripheral vasomotor disturbances, 25% bruxism, 22,5% breathing disturbances, 
20% growth retardation, 20% intense eye communication - «eye pointing», 17,5% scoliosis or 
kyphosis, 15% impaired sleep pattern, 10% inappropriate laughing or screaming spells. 
Diminished response to pain was not described in the majority of the articles included. 
 Only 7,4% of the patients with CDKL5 mutation and 27,5% of the patients with FOXG1 
mutation meet the five out of the eleven supportive criteria. 
Only 5% of the individuals with the CDKL5 mutation and 2,5% of the individuals with 
the FOXG1 mutation met the diagnostic criteria for RTT variant.    
Diminished response to pain was not described in the majority of the articles reviewed. 
 
Other clinical characteristics  
 
 All the FOXG1 mutated patients presented with severe intellectual disability, while 
only 3% with CDKL5 mutation did not have severe intellectual disability.  
 Regarding the presence of GI disturbances, they were evident in 15,7% of the CDKL5 
patients, and in 37,5% of the FOXG1 patients. The most common were gastroesophageal reflux 
disease (GERD), constipation and dysphagia. 
 Feeding disturbances were more frequently described in patients with mutations in 
the FOXG1 (47,5% vs 5,8% on the patients with CDKL5 mutation).  
 Epilepsy was present in 98,3% of the CDKL5 patients with a median age of onset of 1,5 
months (minimum: 0,2; maximum: 11 months), and in 57,5% of the FOXG1 patients with a 
median age of onset of 6 months (minimum: 4; maximum: 11 months). Infantile spasms were 
described in 57,0% of the CDKL5 patients, and in 12,5% of the FOXG1 patients. Refractory 
epilepsy was identified in 66,4% of patients, but data on 29% was not available. Only 7,5% of 
patients with FOXG1 mutations were reported to have refractory epilepsy. EEG revealed 
hypsarrhytmia in 12% on the CDKL5 group (13 from 108 pathological EEG patterns) and 7,6% (1 
from 13 pathological EEG patterns). 
Concerning the brain MRI (Magnetic Resonance Imaging), 36 out of 71 CDKL5 patients 
who performed a MRI (50%) presented with abnormalities, the most common being frontal 
atrophy.  On the other hand, 28 out of the 35 FOXG1 patients (80%) who performed a MRI 
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presented with a brain abnormality  the most common being corpus callosum 
hypoplasia/agenesia (Table 3). 
 
  Table 2 – Overall Results 
 
 CDKL5 FOXG1 
 % (N) 
Female gender 93,5% (113) 78,9% (30) 
Severe intellectual disability 95,6% (109) 100% (40) 
A period of regression followed 
by recovery or stabilization 
16,5% (20) 22,5% (9) 
1. Partial or complete loss of 
acquired purposeful hand skills 
4,1%(5) 2,5% (1) 
2. Partial or complete loss of 
acquired spoken language 
5,0% (6) 0% (0) 
3. Gait abnormalities: Impaired 
(dyspraxic) or absence of ability 
86,8% (105) 90% (36) 
4. Stereotypic hand movements 
such as hand 
wringing/squeezing, 
clapping/tapping, mouthing and 
washing/rubbing automatisms 
78,5% (95) 87,5% (35) 
At least 2 of the 4 main criteria 73,6% (89) 77,5% (31) 
1. Breathing disturbances when 
awake 
19% (23) 22,5% (9) 
2. Bruxism when awake 12,4%(15) 25% (10) 
3. Impaired sleep pattern 21,5% (26) 15% (6) 
4. Abnormal muscle tone 77,7% (94) 80% (32) 
5. Peripheral vasomotor 
disturbances 
25,6% (31) 35% (14) 
6. Scoliosis/kyphosis 14% (17) 17,5% (7) 
7. Growth retardation 16,5% (20) 20% (8) 
8. Small cold hands and feet 11,6% (14) 37,5% (15) 
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9.Inappropriate 
laughing/screaming spells 
9,1% (11) 10% (4) 
10. Diminished response to pain 1,7% (2) 0% (0) 100% Unknown 
11. Intense eye communication - 
«eye pointing» 
13,2% (16) 20% (8) 
5 out of 11 supportive criteria 7,4% 27,5% (11) 
Rett variant criteria 
accomplished 
5% (6) 2,5% (1) 
 
Table 3 – Cerebral MRI findings in patients with CDKL5 and FOXG1 mutation 
 
 CDKL5 (N) FOXG1 (N) 
Performed Cerebral MRI 71 35 
Pathologic findings 36 28 
Cortical and subcortical 
atrophy 
28 2 
Myelination defects - 7 
Abnormal white matter 
signal 
- 5 
Corpus callosum 
hypoplasia/agenesia 
2 20 
Lateral ventricles 
asymmetry 
2 - 
Cortical dysplasia 1 - 
Syringomielia 1 - 
Dysplasic hippocampus - 1 
Right hippocampal lesion 1 - 
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Discussion 
 
As mentioned before, according to the Neul et al (2010) diagnosis criteria, the 
diagnosis of a RTT variant is based on (see table 4):  
 
1. A period of regression followed by recovery or stabilization 
2. At least 2 of the 4 main criteria 
3. 5 out of 11 supportive criteria 
 
According to the new criteria most of the individuals previously diagnosed with a RTT 
variant, would, actually, not fit this diagnosis given that they do not meet all the necessary 
criteria to the diagnosis. Only 5% (N=6) of the individuals with the CDKL5 mutation and 2,5% 
(N=1) of the individuals with the FOXG1 mutation met the diagnostic criteria for RTT variant. 
Most of them did not present regression (83,5% of the CDKL5 patients and 77,5% of the FOXG1 
patients), and even though a majority was described as presenting 2/4 of the main criteria 
(73,6% of the CDKL5 mutated patients  and 77,5% of the FOXG1 mutated patients), an 
important percentage did not present with 5/11 of the supportive criteria, also necessary to 
the diagnosis (92,6% of the CDKL5 mutated patients and 72% of the FOXG1 mutated patients). 
However, it is important to take into account that most of the articles analyzed were published 
before the publication of these criteria. Therefore, they may not provide a description of all 
the criteria necessary to the diagnosis. In addition, the patients described may have been 
studied before regression ensued, or regression could have gone unnoticed. 
Interestingly, two of the main criteria: “partial or complete loss of acquired purposeful 
hand skills” and “partial or complete loss of acquired spoken language”, were rarely met since 
the majority of patients never acquired neither hand skills nor language. This raises the 
question on whether absence of acquisition of hand skills or language should be included in 
the criteria for the diagnosis of these patients, as it happens with the gait criteria (“Gait 
abnormalities: Impaired (dyspraxic) or absence of ability”). 
In addition, the high prevalence of epilepsy in patients with mutations in CDKL5 or in FOXG1 
(less evident in the latter), raises the question of whether epilepsy should be considered as 
supportive or even essential criteria. 
Regarding the limitations of our study: it is important to note that the lack of 
information on some of the required criteria for variant RTT diagnosis may lead to 
underdiagnosis of some of the cases (it could happen that the patients actually met the criteria 
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but the authors didn’t identify or reported on them). Also, even though we tried to be as 
thorough as possible in the search for relevant articles, some relevant but unpublished reports 
may be missing. Nevertheless, this limitation might have been overcome taking into account 
the significant number of case reports included and the estimated low prevalence of 
CDKL5/FOXG1 mutation syndromes. 
Accurate analysis of these data allowed us to point out the most important and 
distinctive characteristics of the individuals with the CDKL5 and FOXG1 mutations. 
CDKL5 
 According to the literature revised, epileptic encephalopathy is the core symptom of 
CDKL5 -related disorders (44-47), which is in agreement with our results.  In our analysis, the 
majority of the patients with CDKL5 mutation had early-onset epilepsy episodes. In the 
literature, various epileptic phenotypes have been described, but a 3-stage evolution proposed 
by Bahi-Buisson et al (2008) summarized the evolution of the CDKL5-related epileptic 
encephalopathy (45): early epilepsy (stage 1), then infantile spasms (stage 2) and, finally, 
multifocal and refractory myoclonic epilepsy (stage 3). Infantile spasms and refractory 
myoclonic epilepsy are frequent but not always present in CDKL5 mutation patients (20, 39, 
40, 42-44, 46-65).  
 Almost all the patients showed hand stereotypies, the most frequent being hand 
mouthing and clapping. These movements usually appeared in the first year of life, but their 
evolution is unknown(51).  
 Rett-like neurovegetative symptoms such as breathing disturbances, cold extremities 
and gastrointestinal disturbances were not as common as they are in Classical RTT. Finally, 
childhood-onset scoliosis was uncommon in CDKL5 mutation patients. 
 Cerebral nonspecific abnormalities were found in the majority of the patients with a 
pathologic MRI. Cortical atrophy (frontal atrophy was the most described feature) combined 
with hyperintensities in the temporal lobe white matter were the most common 
abnormalities. 
 The male patients described had a more severe encephalopathy and virtually no 
acquisition of motor skills compared with the CDKL5 mutation females. Rett-like features have 
not been described in males with CDKL5 point mutations (40, 57, 61, 66, 67). 
 
FOXG1 
  Patients with FOXG1 mutation are characterized by a normal delivery, followed by 
severe presentation, excluding the classic period of regression necessary to the diagnosis of 
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RTT. The early-onset deceleration of head growth progressively resulting in absolute 
microcephaly before 4 months of age is almost always seen. (1, 28, 30, 31, 68-70).  According 
to the literature, a relative preservation of eye contact - though not as intense eye gaze as the 
eye pointing of classical RTT - is also a common feature, which was present in 20% of the 
patients analyzed. 
According to our data, a large percentage of the patients had feeding difficulties and 
features of autonomic origin, such as cold and hypotrophic extremities and abdominal 
bloating. This is in agreement with previous studies, and also with the fact that more patients 
with FOXG1 mutation had 5/11 supportive criteria (27,5% vs only 7,4% of the patients with 
CDKL5 mutation). Thus, the supportive criteria are more commonly met in patients with 
mutations in FOXG1. 
Patients showed intense hyperkinetic movement disorders with polymorphic midline 
stereotypies and jerklike movements mainly consisting of axial and limb myoclonia. Moreover, 
they had bruxism and repetitive protrusive tongue movements. Epilepsy is also a frequent 
feature (32), the EEG pattern does not suggest any specific epilepsy syndrome. In the vast 
majority of cases and in contrast with CDKL5 -related disorders, seizures were easily controlled 
by antiepileptic drugs. 
An elevated percentage of patients with FOXG1 mutation presented a pathologic MRI. 
The most typical MRI pattern, according to our data and with the literature, is the 
hypoplasia/agenesia of the corpus callosum. Thus, this abnormality constitutes a key feature of 
FOXG1 -related encephalopathy (34, 36). 
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Conclusion 
 
 
In conclusion, according to the new criteria for diagnosis of RTT and RTT variants, only 
5% of the CDKL5 patients, and 2,5% of the FOXG1 patients previously reported would meet the 
criteria for diagnosis of RTT variant. In addition, these patients share few key characteristics of 
RTT, and most lack the mandatory regression of development. Also, as many authors have 
already stated, these individuals present specific features, (1). Consequently, one should be 
open to the possibility that mutations in these two genes and the respective associated 
phenotypes may be considered as new independent entities. Still, it is important to take into 
consideration that some of the articles used were not very detailed in the description of the 
patients, not providing all the necessary information for the diagnosis using the new criteria, 
and also, that the patients described may have been studied before regression, or regression 
could have gone unnoticed (as mentioned before). 
 
Finally, we should suspect that a patient has a mutation in the CDKL5 gene if is female 
and has severe intellectual disability, gait abnormalities (impaired or absence), absence of 
hand skills and language, stereotypies (most hand mouthing and clapping) and refractory 
epilepsy starting at 1,5 months with infantile spasms.  
Other common clinical characteristics that might help the diagnosis are: the presence of 
hypotonia and impaired sleep pattern. The finding of frontal atrophy documented on MRI may 
also be helpful. 
We should suspect that a patient has a mutation in the FOXG1 gene if it has an early 
global development delay or severe intellectual disability, gait abnormalities (impaired or 
absence) – grossly abnormal initially development and stereotypies, absence of hand skills and 
language.  
Other common clinical characteristics that might help the diagnosis are: hypotonia, epilepsy, 
usually controlled with therapy; feeding disturbances, small cold hands and feet and peripheral 
vasomotor disturbances, GI disturbances, bruxism and breathing disturbances. In this context 
an abnormal MRI usually with corpus callosum hypoplasia/agenesia may also suggest FOXG1 
mutations. 
 
 Our study expands the current knowledge of this group of neurodevelopmental 
disorders since it provides original information that can help physicians to lessen the 
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unnecessary requisition of a genetic screening test for the MECP2 mutation based on 
phenotype.  
Although classical RTT has been described quasi-exclusively in girls, FOXG1 and CDKL5 -
related mutations have been identified in both female and male patients, showing the 
importance of screening in both female and male patients with an emerging developmental 
profile suggestive of the mutation. 
Our results support the concept that developing longitudinal studies is of paramount 
importance to uncover the natural history of patients with mutations either on CDCKL5 or 
FOXG1.  
 Future reports of patients with the diagnosis of Rett variant according to the revised 
criteria from Neul et al., will certainly clarify CDKL5 and FOXG1 phenotypes. However, it is 
important that the authors are as thorough as possible and report on other comorbidities that 
may be helpful on completing the clinical picture of these disorders.   
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